We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


CPAP Helps To Suppress Tumorigenesis in Oral Cancer

CPAP Helps To Suppress Tumorigenesis in Oral Cancer content piece image
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Oncotarget published "Loss of CPAP causes sustained EGFR signaling and epithelial-mesenchymal transition in oral cancer" which reported that not only do the abnormal functions of microtubule and microtubule-organizing centers such as centrosomes lead to cancers, but also the malignant tissues are characterized by aberrant centriolar features and amplified centrosomes.

In this study, the authors show that the loss of expression of a microtubule/tubulin binding protein, centrosomal protein 4.1-associated protein, which is critical for centriole biogenesis and normal functioning of the centrosome, caused an increase in the EGFR levels and its signaling and, enhanced the EMT features and invasiveness of OSCC cells.

Further, depletion of CPAP enhanced the tumorigenicity of these cells in a xeno-transplant model. Importantly, CPAP loss-associated EMT features and invasiveness of multiple OSCC cells were attenuated upon depletion of EGFR in them.

On the other hand, they found that CPAP protein levels were higher in EGF treated OSCC cells as well as in oral cancer tissues, suggesting that the frequently reported aberrant centriolar features of tumors are potentially a consequence, but not the cause, of tumor progression.

Overall, these novel observations show that, in addition to its known indispensable role in centrosome biogenesis, CPAP also plays a vital role in suppressing tumorigenesis in OSCC by facilitating EGFR homeostasis.

Dr. Radhika Gudi and Dr. Chenthamarakshan Vasu from The Medical University of South Carolina said, "Head and neck squamous cell carcinoma (HNSCC) represents the sixth most common cancer with more than 600,000 new patients diagnosed worldwide and it is linked to more than 300,000 deaths every year."

EGFR is significantly altered in OSCC and its prolonged signaling is mitogenic, driving uncontrolled proliferation of tumor cells.

Despite these advances in the understanding of EGFR signaling, the regulatory mechanisms underlying EGFR signaling and their effects on cancer initiation, progression and metastasis are not fully understood.

Recent studies have shown that microtubule inhibition causes EGFR inactivation or increases the sensitivity to EGFR targeting drugs in various cancers including OSCC.

Microtubules and microtubule-organizing centers have multiple roles in cellular functions including homeostasis of cell signaling, formation of cilia, cytoskeletal actin organization, and centrosome/centriole duplication and normal cell division.

Paradoxically, however, they show not only that EGFR signaling, which is known to contribute to EMT, upregulates the cellular levels of CPAP in OSCC cells, but also detected higher CPAP protein levels in OSCC tumors.

The Gudi/Vasu Research Team concluded in their Oncotarget Research Output that while it has been reported before that EGF stimulation endows OSCC cells with stem cell-like properties, increased invasiveness, and tumorigenic properties, the molecular mechanisms underlying the regulation of EGF induced EMT and tumorigenicity were not known.

Hence, this study does begin to shed light on the molecular mechanisms by which centrosome/MTOC associated proteins are involved in preventing tumorigenesis.

Nevertheless, additional studies are needed in the future to address the mechanism by which CPAP suppresses EGFR dependent EMT and tumorigenesis.

Reference: Gudi RR, Janakiraman H, Howe PH, Palanisamy V, Vasu C. Loss of CPAP causes sustained EGFR signaling and epithelial-mesenchymal transition in oral cancer. Oncotarget. 2021;12(8):807-822. doi: 10.18632/oncotarget.27932

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.